Prostaglandin F2 alpha mediates platelet-activating factor-stimulated atrial natriuretic factor release from the isolated rat heart.
Platelet-activating factor (PAF) and the prostaglandins have recently been shown to stimulate atrial natriuretic factor (ANF) secretion from the heart. As PAF also potentiates the release of cyclooxygenase products from isolated hearts, the role of these substances in PAF-induced ANF secretion was investigated. Using an isolated perfused rat heart preparation, cyclooxygenase inhibition by indomethacin or meclofenamic acid (10 microM for each) significantly attenuated the rise in ANF associated with PAF administration (2.5 nmol). Prostaglandin F2 alpha (PGF) produced an immediate and dose-dependent increase in ANF secretion, which was significant at 0.01 mumol and reached 348 +/- 66% over baseline values after a 1-mumol injection. Prostaglandin E2 (PGE) generated a much smaller 98 +/- 25% increase after a 1-mumol administration. Furthermore, PGF but not PGE was released from isolated hearts immediately after PAF administration. PGF release reached a maximum of 0.06 nmol/min g Heart-1 1 min after PAF stimulation and had returned to undetectable baseline values by 6 min. Cyclooxygenase inhibition abolished the release of PGF after PAF, in addition to attenuating (by 60-70%) the increased secretion of ANF after PAF injection. These results demonstrate very clearly that PGF is the major mediator for PAF-stimulated ANF secretion. Such an interaction may provide an alternative mechanism to atrial distension for the secretion of ANF in pathologies such as myocardial infarction, where autacoids such as PAF and the PGs are released from damaged cardiac muscle and elevated plasma levels of ANF are observed.
Rayner
T E
TE
Department of Medicine, Flinders Medical Centre, Bedford Park, South Australia.
Chen
B N
BN
McLoughlin
J W
JW
Menadue
M F
MF
Norman
R J
RJ
Oliver
J R
JR
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000378:metabolism*; D015237:Dinoprost / Q000494:pharmacology*; D015232:Dinoprostone / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate / Q000187:drug effects; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D008469:Meclofenamic Acid / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects; D010477:Perfusion; D010972:Platelet Activating Factor / Q000494:pharmacology*; D011458:Prostaglandins E / Q000378:metabolism; D011460:Prostaglandins F / Q000378:metabolism; D051381:Rats
D010972:Platelet Activating Factor; D011458:Prostaglandins E; D011460:Prostaglandins F; C472610:atrial natriuretic peptide, rat; D008469:Meclofenamic Acid; D009320:Atrial Natriuretic Factor; D015237:Dinoprost; D015232:Dinoprostone; D007213:Indomethacin